Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil


Summary
Background Reports suggest that COVID-19 vaccine effectiveness is decreasing, but whether this reflects waning or new SARS-CoV-2 variants—especially delta (B.1.617.2)—is unclear. We investigated the association between time since two doses of ChAdOx1 nCoV-19 vaccine and risk of severe COVID-19 outcomes in Scotland (where delta was dominant), with comparative analyses in Brazil (where delta was uncommon).

Methods In this retrospective, population-based cohort study in Brazil and Scotland, we linked national databases from the EAVE II study in Scotland; and the COVID-19 Vaccination Campaign, Acute Respiratory Infection Suspected Cases, and Severe Acute Respiratory Infection/Illness datasets in Brazil) for vaccination, laboratory testing, clinical, and mortality data. We defined cohorts of adults (aged ≥18 years) who received two doses of ChAdOx1 nCoV-19 and compared rates of severe COVID-19 outcomes (ie, COVID-19 hospital admission or death) across fortnightly periods, relative to 2–3 weeks after the second dose. Entry to the Scotland cohort started from May 19, 2021, and entry to the Brazil cohort started from Jan 18, 2021. Follow-up in both cohorts was until Oct 25, 2021. Poisson regression was used to estimate rate ratios (RRs) and vaccine effectiveness, with 95% CIs.

Findings 1972,454 adults received two doses of ChAdOx1 nCoV-19 in Scotland and 425,588,839 in Brazil, with longer follow-up in Scotland because two-dose vaccination began earlier in Scotland than in Brazil. In Scotland, RRs for severe COVID-19 increased to 2·01 (95% CI 1·54–2·62) at 10–11 weeks, 3·01 (2·63–3·99) at 14–15 weeks, and 5·43 (4·00–7·38) at 18–19 weeks after the second dose. The pattern of results was similar in Brazil, with RRs of 2·29 (2·01–2·61) at 10–11 weeks, 3·10 (2·63–3·64) at 14–15 weeks, and 4·71 (3·83–5·78) at 18–19 weeks after the second dose. In Scotland, vaccine effectiveness decreased from 83·7% (95% CI 79·7–87·0) at 2–3 weeks, to 75·9% (72·9–77·3) at 14–15 weeks, and 63·7% (59·6–67·4) at 18–19 weeks after the second dose. In Brazil, vaccine effectiveness decreased from 86·4% (85·4–87·3) at 2–3 weeks, to 59·7% (54·6–64·2) at 14–15 weeks, and 42·2% (32·4–50·6) at 18–19 weeks.

Interpretation We found waning vaccine protection of ChAdOx1 nCoV-19 against COVID-19 hospital admissions and deaths in both Scotland and Brazil, this becoming evident within three months of the second vaccine dose. Consideration needs to be given to providing booster vaccine doses for people who have received ChAdOx1 nCoV-19.

Funding UK Research and Innovation (Medical Research Council), Scottish Government, Research and Innovation Industrial Strategy Challenge Fund, Health Data Research UK, Fiocruz, Fazer o Bem Faz Bem Programme; Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.

Copyright © 2021 The author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction Randomised controlled trials and real-world effectiveness studies have shown the considerable short-term protection offered by COVID-19 vaccines against SARS-CoV-2 infection and COVID-19-related hospitalisation and death.‡‡ Wide-scale vaccine deployment now forms a central part of the pandemic control strategy in many countries. ChAdOx1 nCoV-19 (Oxford–AstraZeneca in Scotland; Vaxzevria/Fiocruz in Brazil) has been widely deployed in many countries, with its relative affordability and less stringent storage requirements than mRNA vaccines making it particularly suitable for deployment in low-income and middle-income countries.
Infection rates and severe COVID-19 have increased in several countries that have attained high levels of vaccine coverage. Although this might be attributable to vaccine escape associated with new variants—In particular, delta (B.1.617.2) and to a lesser extent gamma (P.1)—it is also possible that vaccine effectiveness might be decreasing over time.

Potential vaccine waning has been shown in randomised trials, with neutralising antibody titres decreasing over time, and diminishing protection against confirmed infection. Similarly, research indicates BNT162b2 (Pfizer-BioNTech) vaccine boosters offer additional protection over-and-above that achieved by two doses. However, the clinical and real-world relevance of these findings for ChAdOx1 nCoV-19 remains uncertain.

There have been very high rates of SARS-CoV-2 infection, and COVID-19 hospitalisation and death, in Scotland and Brazil. In both countries, vaccine programmes started early and uptake has been high, with ChAdOx1 nCoV-19 administered with a typical interval of 12 weeks between doses. Both programmes initially targeted people at highest risk of severe disease, with health-care workers and older people prioritised. Other vaccines have been used in both countries, with no systematic difference in the vaccine administered across demographic groups in Brazil. In Scotland, ChAdOx1 nCoV-19 was initially preferentially delivered to community-dwelling older people and the clinically vulnerable, whereas its use was subsequently restricted to people aged 40 years and older following concerns around haematological and vascular complications, particularly in young people. Variants of concern have emerged, with delta dominant in Scotland since May, 2021, and gamma common in Brazil since February, 2021.

The differing dominant variants across Scotland and Brazil offers the potential to disentangle vaccine waning from the effects of changes in variants; this also offers the opportunity to explore how effectiveness varies in the context of different dominant variants. We, therefore, assessed the association between time since two-dose vaccination with ChAdOx1 nCoV-19 and the risk of severe COVID-19 outcomes in Scotland and Brazil.

Methods

Study design

We undertook a retrospective, population-based cohort study to investigate the association between time since two-dose vaccination and COVID-19 outcomes. To assess potential waning, we defined population-based cohorts comprising adults who had received two ChAdOx1 nCoV-19 doses in Scotland and Brazil. This allowed the association between time since receiving a second dose and risk of severe COVID-19 symptoms to be investigated, while minimising potential bias due to apparent waning.
arising from natural infection among the unvaccinated over time. To estimate vaccine effectiveness, we defined cohorts that included a comparator of people with no vaccine protection (unvaccinated individuals in Scotland and the earliest follow-up period after first ChAdOx1 nCoV-19 dose in Brazil). We did several sensitivity analyses, including a test-negative design case-control study for confirmed infection.

We used data from the EA VE II study, which brings together data from 5·4 million people in Scotland, covering around 99% of the national population (appendix 2 pp 53–54). Primary care data were linked to laboratory, hospital discharge, death, and vaccination data using a unique identifier. In Brazil, we used three deterministic linked national datasets (appendix 2 pp 55–56): COVID-19 Vaccination Campaign (SI-PNI); Acute Respiratory Infection Suspected Cases (e-SUS-Notifica), which holds clinical and laboratory data from all suspected cases and contact tracing; and Severe Acute Respiratory Infection/Illness (SIVEP-Gripe), which includes all COVID-19 hospitalisations and deaths.

In both countries, we first defined cohorts of two-dose vaccinated people through vaccination records. We excluded children (younger than 18 years), and people who had received any vaccine other than ChAdOx1 nCoV-19, had inconsistent vaccination records (eg, received different vaccine types, or had an interval of <14 days between doses), or had diagnosed previous infection. For estimating vaccine effectiveness, differences in the underlying databases precluded identical approaches for cohort definition. In Scotland, data were available for the entire population, including unvaccinated people. In Brazil, data were only available for individuals who had received a vaccine. To investigate vaccine effectiveness, we studied a cohort of all adults alive in Scotland from May 19, 2021 (when >50% of cases were delta; appendix 2 p 52), with follow-up until Oct 25, 2021. In Brazil, we studied a cohort for which entry started on the date of receiving the first ChAdOx1 nCoV-19 dose (from Jan 18 to Oct 25, 2021).

We followed the STROBE and RECORD reporting guidelines (appendix 2 pp 46–51). The statistical analysis plan was published before we did the analysis.

For Scotland, ethics approvals were obtained from the National Research Ethics Service Committee, Southeast Scotland 02 (reference number 12/SS/0201), and Public Benefit and Privacy Panel for Health and Social Care (reference number 1920-0279). For Brazil, the Brazilian National Commission in Research Ethics approved the research protocol (CONEP approval number 4.921.308).

Exposures and confounders
To assess waning, we compared rates of severe COVID-19 for the reference period of 2–3 weeks inclusive (ie, 14–27 days) from the date of the second dose among the two-dose vaccinated cohort with subsequent fortnightly periods in both Scotland and Brazil. We followed up individuals until they experienced the primary outcome (a composite of COVID-19 hospitalisation or COVID-19 death), death, receipt of another vaccine type, or end of follow-up (Oct 25, 2021, in both countries).

To assess vaccine effectiveness, we classified exposure periods as time-varying. In Scotland, categories were unvaccinated, first-dose control period (0–13 days after first dose), first dose protection (from 14 days after first dose until receipt of a second dose), second dose control period (0–13 days after second dose), and then fortnightly periods thereafter. In Brazil, the same categories were used except that data on the unvaccinated population were not available. The unvaccinated period was the reference group in Scotland, given the artificially low risk seen immediately after the first dose because individuals with COVID-19 symptoms were advised not to attend for vaccination.2 The 0–13 days post-first dose period was the reference group in Brazil.

To reduce potential confounding by changes in variants, we restricted analyses to the period when delta comprised most cases in Scotland (ie, May 19, 2021, onwards; appendix 2 p 52).

The following confounders were adjusted for in both countries: age (5-year bands), sex, socioeconomic position measured by quintiles of deprivation (the Scottish Index of Multiple Deprivation in Scotland and the Indice Brasileiro de Privação in Brazil), calendar week (as categorical), and interval between doses. In Scotland, we additionally adjusted for number and types of comorbidities commonly associated with COVID-19 illness (appendix 2 p 10), body-mass index, and the number of previous SARS-CoV-2 tests (a marker of being in a high-risk occupational group), which were identified from general practitioner records in the 5-year period before December, 2020. In Brazil, macroregion of residence (with interactions between age and time period) and primary reason for vaccination were also adjusted for.

Outcomes
The primary prespecified outcome was severe COVID-19, defined as COVID-19 hospital admission or death (appendix 2 p 45). Secondary outcomes were the individual outcomes of COVID-19 hospital admission, death, and confirmed symptomatic SARS-CoV-2 infection. In Scotland, diagnostic testing was based on RT-PCR; whereas, in Brazil, rapid antigen testing or RT-PCR was used.

Statistical analysis
To assess potential waning, we used Poisson regression to estimate rate ratios (RRs) with 95% CIs in the two-dose vaccinated cohorts, with natural logarithmic of person-years as offset. To test the hypothesis of whether waning occurred, we used two different
First, we looked for statistical evidence of reducing effectiveness by doing a trend test of RRs on the period after vaccination from 2–3 weeks onwards. Second, we assessed whether effectiveness achieved and maintained a minimum acceptable level, adopting the US Food and Drug Administration threshold of achieving a minimum vaccine effectiveness of 50% for the point estimate.\textsuperscript{24,29}

To estimate vaccine effectiveness, Poisson regression was used to compare rates for different post-vaccination periods with the unvaccinated group (in Scotland) or the 0–13 days after the first dose period (in Brazil). Vaccine effectiveness was calculated as (1–RR)×100 from models including comparators with no vaccine protection. Analyses adjusted for the same confounders. Formulae for statistical models are in appendix 2 (p 38).

In Scotland, we applied sampling weights to account for over-representation of some populations (men and women aged 18–40 years), which was a consequence of those registered at multiple general practitioner practices, visitors, and those having left Scotland. These sampling weights were calculated on the basis of the 2020 National Records of Scotland mid-year population estimates in Scotland. All study participants who had...
It is possible that very rapid changes in infection risk could result in residual confounding that has not been accounted for by adjustment for 1-week calendar periods within the cohort analysis. Therefore, a post-hoc incidence-density matched case-control study was conducted for the primary outcome, with exact matching (with ten controls per case) for outcome date, sex, age, and local authority, and statistical adjustment for further covariates. Therefore, cases were defined by having had a COVID-19 hospital admission or death whereas controls had not had this outcome by the date of matching.

For Brazilian analyses, we did a sensitivity analysis to mitigate potential confounding by the emergence of the delta variant (appendix 2 p 57) by restricting the study period up to July 31, 2021. To explore the potential implications of bias arising from the absence of comorbidity information in Brazil, we repeated the main analysis (≥14 days after second dose among the two-dose ChAdOx1 nCoV-19 cohort) excluding covariates for comorbidities in Scotland. Lastly, we also conducted analyses using the same reference period for vaccine effectiveness estimates in Scotland as in Brazil (ie, 0–13 days after first dose vaccination) to explore potential for bias of vaccine effectiveness estimates in Brazil.

All analyses were carried out using R statistical software (versions 4.1.1 and 3.6.1).

Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report.
Results

1972,454 adults received two doses of ChAdOx1 nCoV-19 in Scotland and 42,558,839 in Brazil (table 1; appendix 2 pp 59–60, 65). The number and rate of confirmed symptomatic infections and severe COVID-19 cases (including hospital admissions and deaths ≥14 days after the second dose) among the two-dose ChAdOx1 nCoV-19 cohort in Scotland and in Brazil are shown in table 1. In Scotland, peaks of severe COVID-19 disease and confirmed SARS-CoV-2 infection were observed in July and September, 2021 (appendix 2 pp 61–62), whereas in Brazil, peaks occurred earlier in March and June, 2021 (appendix 2 pp 66–67). Two-dose vaccination in Brazil occurred later than in Scotland (appendix 2 pp 58, 68); therefore, a shorter follow-up duration was possible.

RRs for severe COVID-19 increased with time since receiving two doses of ChAdOx1 nCoV-19 in Scotland and Brazil (figure 1; appendix 2 pp 16, 22). In Scotland, RRs increased to 2·01 (95% CI 1·54–2·62) at 10–11 weeks, 3·01 (2·26–3·99) at 14–15 weeks, and 5·43 (4·00–7·38) at 18–19 weeks, compared with at 2–3 weeks after the second dose. The pattern of results was similar in Brazil, with RRs of 2·29 (95% CI 1·93–2·71) at 10–11 weeks, 3·01 (2·26–3·99) at 14–15 weeks, and 5·43 (4·00–7·38) at 18–19 weeks, compared with at 2–3 weeks. Waning was statistically significant in both countries (p < 0·001; appendix 2 p 20).

In Scotland, vaccine effectiveness (estimated by comparing risks of severe COVID-19 in the two-dose vaccinated group with the unvaccinated group) initially remained relatively stable between 2–3 weeks and 6–7 weeks after the second dose, then decreased up to 18–19 weeks after the second dose (table 2). In Brazil, vaccine effectiveness (estimated by comparing risks with the 0–1 week period following a first dose, which might underestimate protection) was generally lower than in Scotland, increasing up to 4–5 weeks after the second dose, then decreasing up to 18–19 weeks (table 2).

When investigated as separate outcomes, patterns for COVID-19 hospital admissions and COVID-19 deaths were broadly similar in both Scotland (appendix 2 pp 21) and Brazil (appendix 2 pp 22–24) as for the primary composite outcome, although estimates for death were less precise.

RRs increased over time for confirmed symptomatic SARS-CoV-2 infection in both countries, but to a lesser extent than for severe COVID-19 (figure 2; appendix 2 pp 18–19, 25–26). In Scotland, RRs increased to 1·20 (95% CI 1·14–1·27) at 10–11 weeks, 1·22 (1·16–1·30) at 14–15 weeks, and 1·34 (1·26–1·43) at 18–19 weeks, compared with at 2–3 weeks. In Brazil, RRs for infection were 1·66 (95% CI 1·60–1·72) at 10–11 weeks, 1·86 (1·78–1·94) at 14–15 weeks, and 2·18 (2·06–2·30) at 18–19 weeks, compared with at 2–3 weeks (figure 2; appendix 2 pp 25–26).

Subgroup analyses for the primary outcome of severe COVID-19 were difficult to reliably estimate in both Scotland and Brazil because the rapid delivery of vaccination among older groups led to a high level of collinearity between calendar period, dose interval, and length of time since receipt of a second dose (appendix 2 pp 63–64). In Scotland, RRs increased over time for the group aged 18–64 years, but showed no clear pattern among both older groups, although results were based on few events (appendix 2 pp 16–17). By contrast, RRs in Brazil were greater in the 65–79 years age group than in the 18–64 years age group (appendix 2 pp 22–23).

Sensitivity analyses to explore potential ascertainment biases led to broadly similar patterns of findings as the main results. In Scotland, cohort analyses limited to pillar 2 testing, restricted to the 40–64 year age group, and using an incidence-density matched case-control design showed similar results as the main analysis (appendix 2 pp 34–35, 38). In Scotland, vaccine effectiveness against confirmed SARS-CoV-2 symptomatic infection in the test-negative design case-control study decreased between 2–3 weeks and 18–19 weeks after the second dose (table 3). In test-negative design analyses for Brazil, vaccine effectiveness also decreased after 2–3 weeks, but was generally slightly higher than in Scotland, potentially due to differences in circulating variants (table 3). In Brazil, sensitivity analyses with follow-up restricted to July 31, 2021 (before the delta variant became established) yielded similar findings as the main results (appendix 2 p 27). Repeating vaccine effectiveness analyses for Scotland using the same reference period and more limited adjustment as in Brazil suggested that vaccine effectiveness is likely to be consistently under-estimated in Brazil (appendix 2 p 35).
### Table 2: Vaccine effectiveness estimates for ChAdOx1 nCoV-19 against COVID-19 hospital admissions or death by length of time since two-dose vaccination in Scotland and Brazil

<table>
<thead>
<tr>
<th>Time since the second ChAdOx1 nCoV-19 dose (weeks)</th>
<th>Scotland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate ratio</td>
<td>2.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time since the second ChAdOx1 nCoV-19 dose (weeks)</th>
<th>Brazil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate ratio</td>
<td>2.5</td>
</tr>
</tbody>
</table>

### Discussion

Risks of severe COVID-19 increased over a relatively short follow-up duration following second doses of ChAdOx1 nCoV-19 in Scotland and Brazil, indicating waning vaccine effectiveness. In comparison to the period of greatest protection (2–3 weeks after the second dose), RRAs for severe COVID-19 increased to 5.43 (95% CI 4.00–7.38) in Scotland and 4.71 (3.83–5.78) in Brazil at 18–19 weeks. Comparative analyses across both countries with different dominant variants of concern suggests that the findings are unlikely to be accounted for by confounding due to the emergence of the delta variant or trends in infection rates. Quantifying the exact magnitude of waning is challenging, and vaccine effectiveness estimates should be considered with caution given the difficulty of estimating risk among unvaccinated people. However, our findings consistently show substantial waning in both countries.

Randomised trials for ChAdOx1 nCoV-19 have shown short-term effective protection against severe COVID-19 disease; however, research on potential vaccine waning has mainly focused on BNT162b2. Results from a randomised trial showed that vaccine effectiveness against confirmed infection for BNT162b2 reduced from 96.2% (95% CI 93.3–98.1) at 7 days to less than 2 months after the second dose, to 74.7% (72.9 to 76.8) at 4 to 6 months, and recent real-world data showed protection against severe disease was maintained up to 6 months. In Israel, risk of severe COVID-19 among fully vaccinated adults aged 65 years and older was 1.7 times (95% CI 1.0–2.7) higher for those vaccinated in January, 2021, than for those vaccinated in March, 2021. Another study assessing a representative sample of the UK population assessed the association between time since second dose of both ChAdOx1 nCoV-19 and BNT162b2 and new RT-PCR confirmed infections. The findings showed waning protection among 18–64-year-olds with BNT162b2, whereas ChAdOx1 nCoV-19 estimates were imprecise, but suggested a downward trend. Meanwhile, immunological markers such as spike-antibody levels...
appear to fall over a 3–10-week period after the second dose of ChAdOx1 nCoV-19 and BNT162b2 in a population-based study of 552 participants in England and Wales. A test-negative design study (preprint) by Public Health England has suggested waning protection against symptomatic SARS-CoV-2 infection and severe COVID-19, particularly for ChAdOx1 nCoV-19, with vaccine effectiveness estimates for symptomatic infection generally similar to our test-negative design results. However, in the Public Health England study higher temporal trends. Descriptive characteristics for the sample are available in appendix 2 (pp 11–15). *Partially vaccinated: ≥2 weeks after the first dose and before the second dose.

<table>
<thead>
<tr>
<th>Scotland</th>
<th>Brazil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total samples</td>
<td>Positive samples</td>
</tr>
<tr>
<td>Unvaccinated</td>
<td>26 130</td>
</tr>
<tr>
<td>0–1 week after first dose</td>
<td>9 111</td>
</tr>
<tr>
<td>Partially vaccinated†</td>
<td>15 714</td>
</tr>
<tr>
<td>0–1 week after second dose</td>
<td>5 027</td>
</tr>
<tr>
<td>2–3 weeks after second dose</td>
<td>7 141</td>
</tr>
<tr>
<td>4–5 weeks after second dose</td>
<td>8 947</td>
</tr>
<tr>
<td>6–7 weeks after second dose</td>
<td>10 622</td>
</tr>
<tr>
<td>8–9 weeks after second dose</td>
<td>11 258</td>
</tr>
<tr>
<td>10–11 weeks after second dose</td>
<td>14 043</td>
</tr>
<tr>
<td>12–13 weeks after second dose</td>
<td>17 300</td>
</tr>
<tr>
<td>14–15 weeks after second dose</td>
<td>17 421</td>
</tr>
<tr>
<td>16–17 weeks after second dose</td>
<td>15 442</td>
</tr>
<tr>
<td>18–19 weeks after second dose</td>
<td>14 403</td>
</tr>
<tr>
<td>20–21 weeks after second dose</td>
<td>10 596</td>
</tr>
</tbody>
</table>

*In Scotland, vaccine effectiveness was adjusted for age, sex, deprivation, comorbidities, number of at-risk groups, smoking status, blood pressure, body-mass index, health board, interval between doses, and temporal trend. In Brazil, vaccine effectiveness was adjusted for age, sex, deprivation, macroregion of residence, diabetes, obesity, immunosuppression, cardiac disease, pregnancy, puerperal period, chronic kidney disease, and temporal trend. Descriptive characteristics for the sample are available in Appendix 2 (pp 11–15). †Partially vaccinated: ≥2 weeks after the first dose and before the second dose.

Table 3: Vaccine effectiveness estimates for ChAdOx1 nCoV-19 against confirmed SARS-CoV-2 symptomatic infection by length of time since two-dose vaccination in Scotland and Brazil using a test-negative case-control study

By conducting harmonised analyses in contexts with different circulating variants, our study has important strengths that help mitigate these issues. Drawing on data from Scotland and Brazil makes results less prone to confounding by changes in viral variants or other secular trends. In Scotland, we restricted analyses to when the delta variant was dominant, whereas in Brazil, the gamma variant was common. Vaccine delivery to population subgroups differed across the two countries. In Scotland, ChAdOx1 nCoV-19 was mainly administered to older people residing outside of care homes. However, in Brazil, ChAdOx1 nCoV-19 was not targeted at particular demographic groups, making age comparisons potentially more reliable, but potentially making vaccine effectiveness estimates less comparable across countries. Additional strengths include using national databases to assess clinically important endpoints, and a high level of statistical power. Focusing on the two-dose vaccinated population helped to avoid potential bias arising from comparisons with unvaccinated people becoming immune over time through natural infection, the so-called depletion of susceptibles bias. Several limitations should be noted. First, given the highly correlated nature of time since vaccination, calendar time (including circulating variants), and interval between doses, residual confounding remains possible. The prioritisation of older people for early vaccination makes distinguishing between these factors particularly difficult for subgroup analyses, especially in Scotland where high uptake among older people was achieved over a few weeks. Therefore, estimates among older age groups are potentially less reliable in Scotland. Second, there was no information on some important confounders.
However, analyses in Scotland benefited from richer covariate data. Furthermore, data were not available for unvaccinated individuals within Brazil, meaning vaccine effectiveness estimates were based on the early unvaccinated period and symptom onset used for more accurate estimation. Therefore, vaccine effectiveness estimates might differ between Scotland and Brazil due to these methodological differences. Our sensitivity analyses in Scotland suggested the Brazilian results are likely to underestimate vaccine effectiveness at baseline and lead to the magnitude of vaccine effectiveness waning being overestimated. Therefore, we can be more confident that important waning is occurring than quantifying its exact magnitude. Third, underascertainment of outcomes is possible, particularly for infection. We believe this is less likely for hospital admissions and deaths, with both countries having long-standing robust data infrastructure systems. Our test-negative design analysis provides reassurance as to the robustness of our findings for confirmed infection. However, although we excluded individuals who had previous confirmed infection from our analyses, undetected infection and its resultant immunity could nevertheless bias our vaccine effectiveness estimates. Fourth, we did not have access to individual-level information on SARS-CoV-2 variants (except for a very small minority of the population). Although confounding by variant is unlikely in Scotland because nearly all cases were due to delta,16,40 the absence of this information prevents more nuanced assessment of how waning differs across variants, especially given the above methodological differences across countries. Fifth, following our prespecified analysis plan and on the basis of published guidance,41 we did not correct p values for multiple testing. However, we note that statistical tests for waning would have readily met conventional tests for statistical significance if Bonferroni correction was applied. Lastly, Scotland and Brazil have had high infection rates during the period of study compared with other countries. Therefore, our estimates of the magnitude of vaccine effectiveness waning might not be generalisable to countries with low infection rates where waning might be more modest.

Our findings have important implications for vaccination policy. In combination with the emerging immunological and trials data suggesting that vaccine effectiveness declines over time following two-dose vaccination,11,49 our findings highlight the need to consider booster doses. Further evidence in support of booster doses comes from real-world robust data infrastructure systems. Our test-negative design analysis provides reassurance as to the robustness of our findings for confirmed infection. However, although we excluded individuals who had previous confirmed infection from our analyses, undetected infection and its resultant immunity could nevertheless bias our vaccine effectiveness estimates. Fourth, we did not have access to individual-level information on SARS-CoV-2 variants (except for a very small minority of the population). Although confounding by variant is unlikely in Scotland because nearly all cases were due to delta,16,40 the absence of this information prevents more nuanced assessment of how waning differs across variants, especially given the above methodological differences across countries. Fifth, following our prespecified analysis plan and on the basis of published guidance,41 we did not correct p values for multiple testing. However, we note that statistical tests for waning would have readily met conventional tests for statistical significance if Bonferroni correction was applied. Lastly, Scotland and Brazil have had high infection rates during the period of study compared with other countries. Therefore, our estimates of the magnitude of vaccine effectiveness waning might not be generalisable to countries with low infection rates where waning might be more modest. 

Data sharing
A data dictionary covering the datasets used in this study can be found at https://github.com/EA-VE-II/EA-VE-II-data-dictionary. All statistical code used in this study are publicly available at https://github.com/EA-VE-II/Covid-VE. The data used in this study are sensitive and will not be made publicly available.

Acknowledgments
This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19007) with the support of BREATHE—The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). Additional support has been provided through Public Health Scotland and Scottish Government Director General Health and Social Care. The original EAVE project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (11/46/23). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the UK government. The Brazilian component is part of the Fiocruz VigiVac project on continuous digital evaluation of the national anti-COVID-19 immunisation programme. SVK and SA acknowledge funding from an NHS Research Scotland Senior Clinical Fellowship (SCAF/15/02), the MRC (MC_UU_00022/2), and the Scottish Government Chief Scientist Office (SFC/5/17). This partnership between Brazil and Scotland was established through funding from the NIHR (GHRG/16/137/99) using UK aid from the UK Government to support global health research. This study was partially supported by a donation from the Fazer o Bem Faz Bem programme. The authors thank DATASUS for its excellent work in providing unidentified databases. GLW, MLB, and MB-N are employees of Fiocruz, a federal public institution, which manufactures Vaxzevria in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health for the public health service use. All other authors declare no competing interests.

Contributors
SVK, CR, and AS conceived the idea for the study. All authors contributed to the study design, with SVK drafting the statistical analysis plan, TC-S, CR, EV, and BT conducted the statistical analysis, JP checked the analysis code, CR, EV, EM, BT, UA, SAS, and JP had access to individual-level data for Scotland while TC-S, VdAO, and RF-O had access to individual-level data for Brazil. MB-N, VdAO, and MLB organised the data linkage and secured funding for the Brazilian analysis. SVK drafted the manuscript, with assistance from SA, CR and JP accessed and verified the data and analyses for Scotland, while TC-S and VdAO did so for Brazil. All authors critically revised the manuscript and approved the final version for submission.

Declaration of interests
SVK is a member of the UK Government’s Scientific Advisory Group on Emergencies subgroup on ethnicity, the Cabinet Office’s International Best Practice Advisory Group, and was co-chair of the Scottish Government’s Expert Reference Group on Ethnicity and COVID-19. CR reports grants from the Medical Research Council (MRC) and Public Health Scotland, during the conduct of the study, and is a member of the Scottish Government Chief Medical Officer’s COVID-19 Advisory Group, Scientific Pandemic Influenza Group on Modelling, and Medicines and Healthcare products Regulatory Agency Vaccine Benefit and Risk Working Group. AS is a member of the Scottish Government Chief Medical Officer’s COVID-19 Advisory Group and its Standing Committee on Pandemics; he is also a member of the UK Government’s New and Emerging Respiratory Virus Threats Risk Stratification Subgroup and a member of AstraZeneca’s Thrombotic Thrombocytopenic Taskforce. All roles are unremunerated. VdAO, VB, MLB, and MB-N are employees of Fiocruz, a federal public institution, which manufactures Vaxzevria in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health for the public health service use. All other authors declare no competing interests.

Articles
References

